Boceprevir for previously treated chronic HCV genotype 1 infection

New England Journal of Medicine

Volumn 364, Issue 13, 2011, Pages 1207-1217

  Bacon, Bruce R ^a   Gordon, Stuart C ^b   Lawitz, Eric ^c   Marcellin, Patrick ^d   Vierling, John M ^e   Zeuzem, Stefan ^f   Poordad, Fred ^g   Goodman, Zachary D ^h   Sings, Heather L ⁱ   Boparai, Navdeep ⁱ   Burroughs, Margaret ⁱ   Brass, Clifford A ⁱ   Albrecht, Janice K ⁱ   Esteban, Rafael ^j  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c Alamo Medical Research   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h INOVA FAIRFAX HOSPITAL   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BOCEPREVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PLACEBO; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; FATTY LIVER; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; THROMBOCYTE COUNT; VIRUS LOAD;

EID: 79953176289     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1009482     Document Type: Article

References (20)

1. Hepatitis C fact sheet. Geneva: World Health Organization. (http://www.who.int/mediacentre/factsheets/fs164/en.)
2. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:244-451.
3. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:96772.
4. Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int 2008;28:133243.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
6. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004;140:370-81.
7. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
8. Berman K, Kwo PY. Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis 2009;13:429-39.
9. Mederacke I, Wedemeyer H, Manns MP. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs 2009;10:18-19.
10. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:182-738. [Erratum, N Engl J Med 2009;361:1516.]
11. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292-303. [Erratum, N Engl J Med 2010;362:1647.]
12. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
13. Germer JJ, Majewski DW, Rosser M, et al. Evaluation of the TRUGENE HCV 5′NC genotyping kit with the new GeneLibrarian module 3.1.2 for genotyping of hepatitis C virus from clinical specimens. J Clin Microbiol 2003;41:4855-7. [Erratum, J Clin Microbiol 2004;42:3911.]
14. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46:971-81.
15. PegIntron (Peginterferon alfa-2b) product information. (http://www.spfiles.com/pipeg-intron.pdf.)
16. Rebetol (ribavirin USP) prescribing information. (http://www.spfiles.com/ pirebetol.pdf.)
17. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71. [Erratum, N Engl J Med 2004;351:1268.]
18. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:167-380.
19. Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol 2010;24:183-92.
20. Poordad F, Sulkowski M, McHutchison J, et al. High correlation between week 4 and week 12 as the definition for null response to peginterferon alfa (PEG) plus ribavirin (R) therapy: results from the IDEAL trial. Presented at the 61st annual meeting of the American Association for the Study of Liver Diseases, Boston, October 29-November 2, 2010.